Ähnliche Pins
PG4's Phase 3 Trial in Pneumococcal Disease Reads Out
GESCHÄTZT50 % SICHERHEITin 2,3 JahrenClinicalTrials.gov[1] lists 2028-12-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Pfizer's phase 3 trial of PG4 in pneumococcal disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,400 participants. The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are two groups in this study. All participants will be assigned to one of the two groups. This study is seeking participants who are: \- infants0.75Tozorakimab's Phase 3 Trial in Viral Lung Infection and Acute Respiratory Failure Reads Out
GESCHÄTZT50 % SICHERHEITin 1,1 JahrenClinicalTrials.gov[1] lists 2027-11-04 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Tozorakimab in viral lung infection and acute respiratory failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,527 participants. The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.0.75MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out
GESCHÄTZT50 % SICHERHEITin 1,1 JahrenClinicalTrials.gov[1] lists 2027-10-18 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Merck & Co.'s phase 3 trial of MK-8527 in human immunodeficiency virus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,580 participants. Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it0.75Vicadrostat's Phase 3 Trial in Heart Failure Reads Out
GESCHÄTZT50 % SICHERHEITin 1,7 JahrenClinicalTrials.gov[1] lists 2028-05-22 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Boehringer Ingelheim's phase 3 trial of Vicadrostat in heart failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 6,000 participants. This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. T0.75C.Difficile Vaccine's Phase 3 Trial in Clostridoides Difficile Associated Disease Reads Out
GESCHÄTZT50 % SICHERHEITin 2,2 JahrenClinicalTrials.gov[1] lists 2028-12-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Pfizer's phase 3 trial of C.Difficile Vaccine in clostridoides difficile associated disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 32,500 participants. The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question. On average, each person is expected to take part for0.74Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out
GESCHÄTZT50 % SICHERHEITin 1,8 JahrenClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.0.73BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
GESCHÄTZT50 % SICHERHEITin 1,2 JahrenClinicalTrials.gov[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.0.73Maridebart Cafraglutide's Phase 3 Trial in Atherosclerotic Cardiovascular Disease Reads Out
GESCHÄTZT50 % SICHERHEITin 1,8 JahrenClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.0.72PCV21 Vaccine's Phase 3 Trial in Pneumococcal Immunization Reads Out
GESCHÄTZT50 % SICHERHEITin 257 TagenClinicalTrials.gov[1] lists 2027-06-07 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Sanofi's phase 3 trial of PCV21 Vaccine in pneumococcal immunization reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,195 participants. This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™). The study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age. Cohort A will include randomization to three PCV21 formulation groups or one 20vPCV comparator group (Group 1-4, approximately 896 total participants), whereas Cohort B will include randomization to three PCV21 formulation groups only (Groups 1-3, approximately0.72Ibuzatrelvir's Phase 3 Trial in COVID-19 SARS-CoV-2 Infection Reads Out
GESCHÄTZT50 % SICHERHEITnächstes JahrClinicalTrials.gov[1] lists 2027-10-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Pfizer's phase 3 trial of Ibuzatrelvir in covid-19 sars-cov-2 infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,330 participants. The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.0.72MRNA Seasonal Flu Vaccine's Phase 3 Trial in Influenza, Human Reads Out
GESCHÄTZT50 % SICHERHEITin 1,7 JahrenClinicalTrials.gov[1] lists 2028-06-09 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.GSK's phase 3 trial of MRNA Seasonal Flu Vaccine in influenza, human reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 54,000 participants. This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.0.71Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
GESCHÄTZT50 % SICHERHEITin 1,8 JahrenClinicalTrials.gov[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.0.70
Boehringer Ingelheim